Background {#Sec1}
==========

Urinary tract infections (UTI) are very frequently found in humans. The most frequent pathogens are *Escherichia coli* and other species of *Enterobacteriaceae*. Gram-positive bacteria, such as staphylococci and enterococci, and non-fermenting Gram-negative bacteria, such as *Pseudomonas aeruginosa*, can also be found \[[@CR1]\]--\[[@CR4]\]. Funguria due to *Candida spp.* is mainly cultured in patients with risk factors, e.g. immunocompromised or with infections due to foreign bodies \[[@CR5]\],\[[@CR6]\]. The worldwide increasing bacterial resistance has become a general therapeutic problem. In many countries the resistance rates of *E. coli* against trimethoprim and cotrimoxazole, have exceeded the 20% threshold accepted for empiric therapy by far \[[@CR1]\],\[[@CR3]\],\[[@CR7]\]--\[[@CR9]\]. Although in many countries still below 20%, the resistance rates of *E. coli* against fluoroquinolones are also increasing worldwide. Therefore, cotrimoxazole, trimethoprim, fluoroquinolones, the former standard therapeutics for uncomplicated UTI \[[@CR10]\], but also amoxicillin with and without clavulanic acid and oral cephalosporins are no more recommended in many of the current guidelines as first line antibiotics for the treatment of uncomplicated UTI (cystitis) \[[@CR11]\]--\[[@CR13]\]. Older oral antibiotics, such as fosfomycin trometamol, pivmecillinam, and nitrofurantoin, which have still preserved their antibacterial activity against *E. coli* and other uropathogens, are now mostly recommended as first line antibiotics for this indication \[[@CR11]\]--\[[@CR13]\]. But further alternatives should be looked for.

Nitroxoline, 5-nitro-8-hydroxyquinoline, has been described first in the fifties of the last century \[[@CR14]\]. Since the sixties it has been used for treatment and prophylaxis of acute and recurrent UTI \[[@CR15]\],\[[@CR16]\] in adults and children in the European countries. Nitroxoline is active against most Gram-negative and --positive uropathogenic bacteria \[[@CR17]\]--\[[@CR19]\], against mycoplasmas (*M. hominis, Ureaplasma urealyticum*) \[[@CR20]\],\[[@CR21]\] and human pathogenic *Candida spp* \[[@CR22]\],\[[@CR23]\]. The antibacterial activity against *Acinetobacter spp*., *Enterococcus spp*., and *Serratia spp*. is variable and *Pseudomonas spp*. are considered resistant \[[@CR17]\],\[[@CR19]\]. Oral treatment with nitroxoline has no qualitative and quantitative effect on the fecal flora \[[@CR24]\].

The rate of susceptibility of *E. coli*, the leading uropathogen, at a MIC of nitroxoline of ≤8 mg/l is practically 100% and has not changed over the years as shown by a recent in vitro study with 499 strains from patients with community acquired UTI showing MIC~50~- and MIC~90~-values of 2 mg/l and 4 mg/l, respectively. The unimodal MIC distribution indicates that these pathogens are wild types without any acquired resistance \[[@CR25]\]. For other uropathogens, such as *K. pneumonia, P. mirabilis. P. vulgaris, M. morganii, and S. saprophyticus* the MIC~50~- and MIC~90~-values were between 4--8/4--8 mg/l with highest MIC of 8 mg/l \[[@CR26]\]. The MIC~90~ for various *Candida spp.*, such as *Candida albicans, Candida tropicalis, Candida parapsilosis, Candida krusei, Torulopsis (Candida) glabrata*, is between 1 and 4 mg/l nitroxoline \[[@CR27]\], which correlate well with other studies \[[@CR28]\].

The mode of antibacterial and antifungal action is based on the ability of nitroxoline to chelate with various metallic bivalent cations \[[@CR29]\]--\[[@CR31]\]. The antibacterial actvity of nitroxoline is decreased by the presence of Mn^++^ and Mg^++^, but not Ca^++^ and univalent ions like Na^+^ and K^+^. The authors assume that magnesium ions stabilizing the lipopolysaccharide (LPS) molecules in the outer bacterial membrane favour the accumulation of nitroxoline in the bacteria, such as *E. coli*. This process is energy independent. Nitroxoline is binding to bacterial surface structures, which probably leads to an interaction between nitroxoline and magnesium ions complexing with LPS phosphate groups \[[@CR30]\],\[[@CR31]\]. The bacterial surface becomes hydrophobic as demonstrated for *E. coli* at 1/8 of MIC of nitroxoline and the adherence to catheter surface is decreased \[[@CR32]\]. Nitroxoline inhibits rapidly and selectively RNA synthesis in fission yeast by chelation of bivalent cations required for RNA synthesis \[[@CR33]\]. Furthermore, subinhibitory concentrations of nitroxoline have a major inhibitory effect on adhesin expression and bacterial attachment \[[@CR34]\]--\[[@CR36]\], which may add an important antibacterial mechanism of nitroxoline. Nitroxoline also reduces the formation and induces the dispersal of Pseudomonas aeruginosa biofilms by chelation of iron and zinc \[[@CR37]\].

After single oral administration of 200 mg nitroxoline antibacterial urinary activity can be demonstrated by microbiological assays peaking on average between 216 mg/l and 220 mg/l during the urine collection periods 1--2 hours and 3--4 hours \[[@CR38]\]. The HPLC concentrations of free nitroxoline, however, were much lower peaking on average between 3.2 mg/l and 5.8 mg/l during that periods. The discrepancy between the two assays was explained by antibacterial active metabolites in urine, because nitroxoline is excreted in the urine in unconjugated as well as conjugated (glucuronide, sulfate etc.) forms \[[@CR38]\],\[[@CR39]\]. A recent study showed that after oral administration of 250 mg about 99% of the excreted nitroxoline was eliminated as metabolites in urine of volunteers, mainly as sulfate and glucuronide, and only 1.0% as the parent component \[[@CR40]\],\[[@CR41]\]. In this study urinary inhibitory and bactericidal concentrations were determined against selected uropathogens, such as *E. coli, K. pneumonia, P. mirabilis, and S. saprophyticus.* In connection with additional urinary bactericidal kinetic studies it was concluded, that nitroxoline exhibits mainly bacteriostatic activity in urine against susceptible strains. Its antibacterial activity is more pronounced in acidic than in alkaline urine.

The aim of this article is to review systematically the available literature on the use of nitroxoline for treatment and prevention of UTI and to meta-analyse four prospective, randomized, single-blind, multicenter, comparative studies, so far unpublished, in order to improve the evidence based recommendation to use nitroxoline as one of the first line drugs for the treatment of uncomplicated UTI (cystitis).

Methods {#Sec2}
=======

Literature search {#Sec3}
-----------------

A narrative literature search concerning efficacy and safety of nitroxoline in the treatment of UTI was performed by the manufacturing company (Rosen Pharma, Blieskastel, Germany). A total of 26 uncontrolled studies including 1206 patients (947 adults and 259 children) published between 1962 and 1987, two controlled studies including 148 patients (100 adult and 48 children) and one postmarketing observational study \[[@CR42]\] including 9800 patients with uncomplicated and complicated UTI were found (Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"}).Table 1**Total number (n) of published clinical studies on treatment of urogenital infections with nitroxoline as found by the narrative literature search**Study designPopulationStudies (n)Patients (n)UncontrolledAdults15947UncontrolledChildren11259Controlled vs. norfloxacinAdults1100Controlled vs. TMP/SMXChildren148ObservationalAdults19,800**Total2911,154**TMP/SMX -- trimethoprim/sulfamethoxazole.Table 2**Fifteen uncontrolled clinical studies with nitroxoline in 947 adult patients of both genders**First authorYearPat (n)Indication (T/P)DosageDurationSuccess rateAdverse eventsKuss \[[@CR43]\]196272T: acute cUTI & uUTI400 mg/d20--45 days78%1.3% gastrointestinalMoreau \[[@CR44]\]196220T: acute cUTI400--500 mg/d8--10 (−45) days90%5% gastrointestinalv. Rütte \[[@CR45]\]1969200P: chronic rUTI300--500 mg/d2--3 months80%0%shortly 800 mg/d1 dayUhlir \[[@CR46]\]197220T: acute UTI (7), chronic PN (13)300 mg/d14 days100%0%Allal \[[@CR47]\]1973264T: UTI during pregnancy300 mg/d6 days\> 75%No dataBittard \[[@CR48]\]197450P: post-op. catheter7.5--10 mg/kg/d6 weeks92%Few gastrointestinalSchlesinger \[[@CR49]\]197565T: chronic PN (62), chronic prostatitis (3)300--500 mg/d10 days80% clinical0%Aubert \[[@CR50]\]197628T: post-op. catheter, after endoscopy200--300 mg/d10--15 days72%0%Dufour \[[@CR51]\]197915T: acute prostatitis900--1600 mg/d3--5 days81%No dataLenzner \[[@CR52]\]198360T: fungal UTI750 mg/d10--20 days80%3.3% itching; few cases with nausea and vomitingSchülke \[[@CR53]\]198450T: postop., acute UTI after removal of urethral catheter for 3--10 days750 mg/d3 days78%0%Sachse \[[@CR54]\]198444P: chronic rUTI750 mg/d4 months77% free of rUTI; rUTI rate decreased from 0.33 to 0.11/month9% gastrointestinal\
2.2% exanthemaDemontrond \[[@CR55]\]198615T: candiduria in hospitalised patients600 mg/d10--30 days87%0%Frobert \[[@CR56]\]198736T: acute, uUTI in hospitalised patients600 mg/d10 days93% bacteriological5.5% gastrointestinal87% clinical2.7% nausea2.7% dizzinessCancet \[[@CR27]\]19878T: urogenital fungal infections600 mg/d15 days100%no dataT-therapy; P-prophylaxis; UTI-urinary tract infection; uUTI-uncomplicated UTI; cUTI-complicated UTI; PN-pyelonephritis.Table 3**Eleven uncontrolled clinical studies on treatment and prophylaxis of UTI with nitroxoline in 259 children**First authorYearPatients (n)Indication (T/P)DosageDurationSuccess rateAdverse eventsLecornu \[[@CR57]\]197425 childrenT: compl. and uncompl. UTI50--400 mg/d as suspension4--12 days72%8% nausea0--13 yearsRoussel \[[@CR58]\]197424 childrenT: compl. and uncompl. UTI10 mg/kg/d as suspension10 days- 6 months79%0%7 days--6 monthsRaynaud \[[@CR59]\]197419 childrenT: compl. and uncompl. UTI10 mg/kg/d as suspension20 days69%10% nausea0--10 yearsLuckel \[[@CR60]\]197525 childrenP: compl. and uncompl. UTI10--20 mg/kg/d as suspension17--55 days83%0%0--8.5 yearsViville \[[@CR61]\]197522 childrenP: compl. UTI10--30 mg/kg/d as suspension3--6 months86%0%2 months-17 yearsChable \[[@CR62]\]197528 childrenT: compl. and uncompl. UTI10--20 mg/kg/d as suspension10 days81%0%2 month-14.5 yearsBattin \[[@CR63]\]197530 childrenP: compl. and uncompl. UTI10 mg/kg/d as suspension6 weeks90%0%2 month-10 yearsSorez \[[@CR64]\]197530 childrenT: compl. and uncompl. UTI10--25 mg/kg/d as suspension10 -- 17 days73.7% uncompl. UTI\
40% compl. UTI0%10 days-8 yearsNeimann \[[@CR65]\]197521 childrenT/P: compl. and uncompl. UTI25--400 mg/d as suspension4 days-4 months90%10% nausea26 days-8 yearsMachecourt \[[@CR66]\]197623 childrenT: compl. and uncompl. UTI10--20 mg/kg/d as suspension10 days91%0%21 days-14 yearsLambert-Zechovsky \[[@CR24]\]198712 childrenT: uncompl. UTI20 mg/kg/d as suspension10 days66% (91% incl. non-compliance)-aver. 4 yearsn-number; T-therapy; P-prophylaxis; UTI-urinary tract infection.Table 4**Two controlled open clinical studies in a total of 148 patients with nitroxoline (NTX) versus norfloxacin (NFX) or cotrimoxazole (CTX); SMX-sulphamethoxazole; TMP-trimethoprim**First authorYearPat.(n)Indication (T/P)Antibiotic and dosageDurationSuccess rateAdverse eventsSchülke \[[@CR67]\]198651 NTXT: postop., uncompl. UTI750 mg NTX/d vs. 800 mg NFX/d3 days60.8% NTX 59.2% NFX0%49 NFXDodat \[[@CR68]\]198848 childrenP: postop. UTI (ureteral reflux)10 mg NTX/kg/d30--60 days95% NTX6% NTX0--8 yearsvs. 15 mg SMX/ 3 mg TMP/kg/d95% CTX5% CTXT-therapy; P-prophylaxis, UTI-urinary tract infection.

IPD Meta-analysis of four clinical studies {#Sec4}
------------------------------------------

The individual patients' data (IPD) of four prospective, randomized, single-blind, multicenter, comparative studies (data on file, Rosen Pharma GmbH), so far unpublished, were available for this IPD meta-analysis. The four studies were performed to renew marketing registration during December 1992 until 1993 in 20 investigational sites. A total of 466 female patients suffering from acute sporadic cystitis or acute episode of recurrent cystitis was included in the four studies (nitroxoline: n = 234; norfloxacin: n = 54; cotrimoxazole: n = 178). For the meta-analysis the original individual patient's data (IPD) could be analyzed.

The studies were performed in accordance with the declaration of Helsinki updated in Hongkong 1989 \[[@CR69]\]. Before start they were voted positively by the Ethical Commissions of the Medical Councils of Saarland for study NWNF \#10 (dated 7 Sept 1992), Bavaria for study NWNF \#11 (dated 20 October 1992, Nr. 92247), Rheinland-Pfalz for study NWNF \#13 (dated 3 November 1992), and Hessen for study NWNF \# 15 (dated 2 November 1992, Nr. 71/92), and the respective countries of Germany where the studies where performed. A registration in a public trials registry was not required at that time.

### Study design {#Sec5}

The four clinical studies were prospective, randomized, single-blind (patient blinded), multicenter, and comparative in parallel groups. The aim of the studies was to compare the efficacy and safety of nitroxoline versus cotrimoxazole and norfloxacin in female patients with acute uncomplicated sporadic cystitis (NWNF 10, 11, 13) or with acute episode of recurrent uncomplicated cystitis (NWNF 15). In Table [5](#Tab5){ref-type="table"} the main parameters of the design of the four studies are outlined.Table 5**Study design of the four meta-analysed prospective, open, randomised clinical studies in female patients with acute uncomplicated and recurrent cystitis treated with nitroxoline (NTX) versus a control antibiotic, cotrimoxazole (CTX) or norfloxacin (NFX)**StudyNitroxolineControlIndicationPatients (n)DurationEnd of therapy visitTest of cure visitNWNF 10°Nitroxoline (NTX)Cotrimoxazole (CTX)Acute uncompl. cystitis130 total5 daysday 6day 12--143×250 mg2×960 mg67 NTX, 63 CTXNWNF 11Nitroxoline (NTX)Cotrimoxazole (CTX)Acute uncompl. cystitis115 total5 daysday 6day 12--143×250 mg2×960 mg56 NTX59 CTXNWNF 13Nitroxoline (NTX)Norfloxacin (NFX)Acute uncompl. cystitis105 total5 daysday 6day 12--143×250 mg2×400 mg51 NTX54 NFXNWNF 15Nitroxoline (NTX)Cotrimoxazole (CTX)Acute episode of uncompl. recurrent cystitis116 total10 daysday 11--13\*day 21--233×250 mg2×960 mg60 NTX56 CTX°inclusion criteria missing (no urine cultures reported): total 12, NTX 7, CTX 5 patients (included in safety set only).\*additional visit during therapy: day 6--8.

### Selection of patients {#Sec6}

After medical history including kind and duration of symptoms, pretreatment and concurrent medication, physical examination including body temperature, urinalysis and confirmation of the clinical diagnosis including additional tests needed, eligible patients were informed about aim, performance, possible adverse events and their right to terminate the study without giving any reasons. If written informed consent was documented, patients were included into the study after inclusion and exclusion criteria had been checked.

In three studies (NWNF 10, 11, 13) female patients with clinical signs and symptoms of acute sporadic uncomplicated cystitis and in one study (NWNF 15) those with acute episode of recurrent uncomplicated cystitis were included. In all patients a pretreatment midstream or single catheter urine sample was requested to show pyuria (white blood cells \>5 000/ml) and bacteriuria with colony forming units (CFU) ≥ 10^5^/ml due to susceptible pathogens.

According to the study protocol exclusion criteria were: age below 18 years; taking part in a clinical study during the last 30 days; pregnancy; urolithiasis or obstruction within the urinary tract; severe systemic, gastrointestinal, kidney or liver diseases; hypertension; diabetes mellitus; known erythema exsudativum multiforma, pathologic hemogram including hemoglobin anomalies; glucose-6-phosphate-deficiency; acute porphyria; folic acid deficiency; known seizure disorder; and allergy against sulfonyl urea antidiabetics and sulfonamide based diuretics.

### Randomization, treatment, and visits {#Sec7}

Female patients were randomized in two age groups (upto 45 and above 45 years) and received their allocated antibiotic wrapped in a neutral box signed "for clinical study only". Because an objective outcome (eradication of bacteriuria) was the primary aim of the study, a double-blind design was not considered necessary at that time.

Patients in the nitroxoline group were asked to take one capsule containing 250 mg nitroxoline three times daily with the three main meals. Patients of the control group were asked to take one tablet containing 960 mg cotrimoxazole (NWNF 10, 11, 15) or 400 mg norfloxacin (NWNF 13) twice daily with the morning and evening meal. The treatment duration was 5 days in 3 studies (NWNF 10, 11, 13) and 10 days in one study (NWNF 15). The control visits were one day (end of treatment) and 7--13 days (test of cure) after end of therapy. In the ten day treatment study (NWNF 15) an additional visit during therapy at day 6 was scheduled.

#### Primary objectives {#Sec8}

The primary objective was the eradication (CFU \<10^4^/ml) of the bacteriuria due to susceptible pathogens at test of cure in compliant patients (≥80% of medication) without taking any additional antibiotic.

#### Secondary objectives {#Sec9}

Secondary objectives were clinical efficacy and safety. For clinical efficacy the following symptoms were scored (0-absent upto 5-very severe) by the patient: dysuria, frequency, urgency, nycturia, flank/back pain. The clinical efficacy was assessed also globally by the patient and the investigator. At each visit patients were asked for any adverse event, which was documented. The safety was assessed also globally by the patient and the investigator.

The following laboratory tests were performed: Urinalysis (white and red blood cells, nitrite reaction, protein, glucose, pH), serum chemistry (glucose, creatinine, bilirubin, AST, ALT, gammaGT, sodium, potassium, calcium) and hematology (red and white blood count, thrombocytes, blood sedimentation rate).

### Evaluation sets {#Sec10}

The efficacy and safety was analysed in the following patients' sets:

***Safety set:*** All patients included into the study having received any study medication.

***Modified microbiologically Intention-to-Treat Set (mMITT):*** All patients with significant bacteriuria (CFU ≥10^5^/ml) at study entry; with at least one control visit including microbiological investigation, and with a consistent clinical report (in study NWNF 10 few clinical reports were inconsistent). The last observation was brought forward (LOF), if not failure has already been documented and an additional antibiotic been administered.

***Per Protocol Set (PP):*** All patients with significant bacteriuria (CFU ≥10^5^/ml) at study entry; with test of cure visit including microbiological investigation (except failure was already documented and additional antibiotic administered); doubtless randomization; and compliance (≥80% of allocated drug).

***Modified per Protocol Set (mPP):*** All patients with significant bacteriuria (CFU ≥10^5^/ml) at study entry; with test of cure visit including microbiological investigation; missing test of cure visit was rated as failure (worst case) \[[@CR70]\]; doubtless randomization; and compliance (≥80% of allocated drug).

### Statiscial analysis {#Sec11}

The individual patient data were entered and independently checked to ensure high data quality. Categorial data are described by absolute and relative frequencies. Ordinal data are either described in tables by absolute and relative frequencies (global clinical assessment) or by box plots (scoring of clinical symptoms). For numerical data median as well as minimum and maximum value are given.

To evaluate the noninferiority of nitroxoline compared to the controls with regard to the failure rate the difference of the failure rates of the two treatments and its 95%-confidence interval is estimated \[[@CR71]\]. Odds Ratios are estimated, too. Difference as well as odds ratio are estimated by logistic regression with random center effect \[[@CR72]\]. Since the proportion of variance explained by the centers exceeded substantially the proportion of variance explained by the four studies random center effects instead of random study effects were added to the model. Wether the distribution of ordinal data is the same in the two treatment groups is analyzed by ordered probit regression, the distribution of numerical data is compared by linear regression. For both approaches random center effects are taken into account.

All p-values are two-sided, the level of significance is set to 0.05. Stata/IC 13.1 was used for data preparation and statisical analysis.

Results {#Sec12}
=======

Literature search {#Sec13}
-----------------

The 26 uncontrolled clinical studies published between 1962 and 1987 included a total of 1206 patients (947 adults and 259 children) (Table [1](#Tab1){ref-type="table"}). Nitroxoline was mainly administered for treatment of uncomplicated and complicated UTI as well as for prophylaxis of recurrent UTI with daily dosages mostly between 300 and 900 mg. The treatment duration varied mainly between 3 and 10 days depending on the indication. Study details are presented in Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}.

The summary results of the two controlled studies including 148 patients (100 adult and 48 children) are outlined in Table [4](#Tab4){ref-type="table"}. In one study 51 patients received 250 mg nitroxoline tid versus 49 patients 400 mg norfloxacin bid for treatment of postoperative and uncomplicated UTI \[[@CR67]\]. The microbiological outcome was comparable in both groups (about 60%); no adverse events were reported. The second controlled study was performed in 48 children with ureteral reflux \[[@CR68]\]. The children received either nitroxoline or cotrimoxazole for prophylaxis of UTI for 30--60 days. In 95% of the children a recurrent UTI could be prevented in both groups. Adverse reactions were reported in 6% with nitroxoline and in 5% with cotrimoxazole.

The postmarketing observational study included 9800 patients (75% women, 25% men) with complicated and uncomplicated UTI including recurrent UTI, and to a lesser extent also with fungal urogenital infections \[[@CR42]\]. The dosage of nitroxoline was fixed at 250 mg tid, but the treatment duration was chosen according to the physician's decision. The physician's assessment revealed clinical success of 95% in cystitis, 79% in recurrent and complicated UTI; 80% in pyelonephritis, and 91% in fungal infections. The overall patient's assessment of success was 95%. Only 2.2% of the patients reported adverse events overall including 1.8% gastrointestinal and 0.3% allergic adverse events.

IPD meta-analysis {#Sec14}
-----------------

### Patients {#Sec15}

The studies were performed in 20 German cites from Dezember 1992 until 1993. A total of 466 female patients (nitroxoline: n = 234, controls: norfloxacin: n = 54; cotrimozazole: n = 178) was included in the four clinical studies. In the IPD meta-analysis the results obtained from patients in the nitroxoline group were compared with those obtained from patients in the control groups, norfloxacin and cotrimoxazole.

### Demography, history and physical examination {#Sec16}

In Table [6](#Tab6){ref-type="table"} some data concerning demography, history and physical examination are compared between nitroxoline and controls in the safety set. A significant difference was only found as a slightly higher body mass index, higher systolic blood pressure and a lower proportion pretreated by antibiotics in the group of the controls. Both groups included about the same number of patients upto 45 and above 45 years. Although diabetes mellitus and hypertension, considered as exclusion criteria in the original protocol, was found in some patients in both groups, these patients were not excluded from the meta-analysis, because these underlying diseases were considered only minor protocol violations.Table 6**Demography, history, and physical parameters of female patients investigated in the safety set**NitroxolineControlsp-valueDemographic parameternMedian (range)nMedian (range)Age (years)23448 (18--89)23247 (18--85)0.520-up to 45 years234113 (48.3%)232115 (49.6%)0.745Height (cm)234165 (150--185)231165 (145--187)0.290Weight (kg)23462 (43--100)23264 (42--102)0.125Body mass index (kg /m^2^)23423.0 (15.9--41.3)23123.2 (15.6--38.0)0.038Heart rate (min ^−1^)23180 (52--172)23180 (56--120)0.354Systolic BP (mmHg)232120 (80--195)231130 (100--190)0.025Diastolic BP (mmHg)23280 (60--120)23180 (50--120)0.410No hypertension (SBP ≤ 140 mmHG)232165 (71.1%)231137 (59.3%)0.004Mild hypertension (SBP \> 140 mmHG)23246 (19.8%)23163 (27.3%)Moderate hypertension (SBP \> 160 mmHG)23217 (7.3%)23122 (9.5%)Severe hypertension (SBP \> 180 mmHG)2324 (1.7%)2319 (3.9%)Diabetes mellitus23411 (4.7%)2326 (2.6%)0.230Duration of urinary symptoms (d)1653 (1--30)1683 (1--21)0.442Pretreatment with antimicrobials\*23416 (6.8%)2328 (3.4%)0.060Only unspecific pretreatment^\#^23425 (10.7%)23228 (12.1%)0.667\*antibiotics, chemotherapeutics.^\#^spasmolytics, analgetics, tea etc.

### Flow of patients {#Sec17}

In Figure [1](#Fig1){ref-type="fig"} the total number of patients included in the studies is shown, randomized to nitroxoline and controls and excluded because of different reasons from the evaluation sets. Finally the safety (mMITT/mPP/PP) set comprised 234 (211/205/200) patients in the nitroxoline and 232 (213/210/206) in the control groups.Figure 1**Diagram showing flow of patients participating in the four studies on treatment with nitroxoline or with a contol antibiotic, cotrimoxazole or norfloxacin.** mMITT-modified microbiological intention to treat; mPP-modified per protocol; PP-per protocol.

### Quality of the studies {#Sec18}

Each of the four randomized clinical trials achieved a good quality with four out of maximum five Jadad scores \[[@CR73]\],\[[@CR74]\]: randomization (1 score), which was appropriate (1 score), patient blinding only (0 score), which was appropriate (1 score), and drop-outs well-grounded (1 score).

### Bacterial spectrum and resistance to study drugs {#Sec19}

The bacterial spectrum and resistance at study entry (visit 1) is shown in Table [7](#Tab7){ref-type="table"}. On average about 10% of the patients were included with mixed infections. Therefore the total number of isolates were higher than the number of patients included. *Escherichia coli* was the most frequent pathogen in all studies ranging from 65% to 73% of all isolates. The percentages of resistant isolated to nitroxoline ranged from 0% to 5.5% and that to the control antibiotics from 0.8% to 5.2%. There was no evidence, that patients with recurrent UTI (study NWNF 15) showed more resistant strains than patients with sporadic UTI (studies NWNF 10,11,13).Table 7**Bacterial spectrum and resistance (R) against nitroxoline (Ni) versus controls (C), cotrimoxazole or norfloxacin, at study entry (visit 1)**Study Nr./RNWNF 10R(n)NWNF 11R(n)NWNF 13R(n)NWNF 15R(n)NWNF 10--13R(n)NWNF 10--15R(n)Bacterial isolatesn (%)Ni/Cn (%)Ni/Cn (%)Ni/Cn (%)Ni/Cn (%)Ni/Cn (%)Ni/C*E. coli*82(67.2%)-/188(65.3%)1/681(67.0%)−/−98(73.0%)−/−251(66.4%)1/7349(68.2%)1/7*Proteus spp*.\*20(16.4%)−/−9(6.7%)−/−8(6.6%)−/−12(9.0%)−/−37(9.8%)−/−49(9.6%)−/−*Klebsiella spp*.1(0.8%)−/−5(3.7%)−/−1(0.8%)−/−6(4.5%)−/−7(1.9%)−/−13(2.5%)−/−*Enterobacter spp*.\--2(1.5%)−/−3(2.5%)−/−7(5.2%)-/25(1.3%)−/−12(2.3%)-/2*Citrobacter spp*.2(1.6%)−/−-−/−1(0.8%)−/−1(0.8%)−/−3(0.8%)−/−4(0.8%)−/−Enterococci9(7.4%)−/−13(9.7%)6/113(10.7%)-/12(1.5%)−/−35(9.3%)6/237(7.2%)6/2Staphylococci5(4.1%)−/−7(5.2%)−/−13(10.7%)1/-8(6.0%)−/−25(6.6%)1/-33(6.4%)1/-Streptococci2(1.6%)−/−2(1.5%)−/−1(0.8%)−/−-−/−5(1.3%)−/−5(1.0 %)−/−Others1(0.8%)−/−9(6.7%)−/−-−/−-−/−10(2.6%)−/−10(2.0%)−/−**Total**122(100%)-/1135(100%)7/7121(100%)1/1134(100%)-/2378(100%)8/9512(100%)8/11-/0.8%5.2/5.2%0.8/0.8%-/1.5%2.1/2.4%1.6/2.1%Isolates/patients122/122135/115121/105134/116378/350512/466(1.0)(1.17)(1.15)(1.16)(1.08)(1.1)\*indol positive and negative strains.

### Microbiological outcome {#Sec20}

The micobiological outcome (eradication of bacteriuria \<10^4^/ml) as primary study aim is shown in Table [8](#Tab8){ref-type="table"}. In all three evaluation sets the eradication rates were above 90% in the nitroxoline and in the control groups. The 95% confidence intervals (CI) of the estimated eradication rate differences met statistical non-inferiority compared to the controls (10% non-inferiority margin) in all three evaluation sets.Table 8**Microbiological success (eradication of bacteriuria) in the different evaluation sets**Evaluation setNitroxolineControlsDifference (%) (95%-CI)Odds ratio (95%-CI)mMITT192/211 (91.0%)203/213 (95.3%)−3.4 (−9.7 to 3.0)0.47 (0.21 to 1.06)PP184/200 (92.0%)197/206 (95.6%)−2.2 (−8.2 to 3.7)0.47 (0.19 to 1.14)mPP185/205 (90.2%)197/210 (93.8%)−2.9 (−9.9 to 4.1)0.60 (0.28 to 1.27)mMITT-modified microbiological intention to treat; PP-per protocol; mPP-modified per protocol.Difference: nitroxoline -- controls.Odds Ratio: nitroxoline vs controls.Estimation by logistic regression with random center effect.

Figure [2](#Fig2){ref-type="fig"} shows the 95% CI of the individual studies and the total result of the four meta-analysed studies together in the mMITT and the PP sets with the contributing weight of each study.Figure 2**Estimated difference (95%-confidence interval) between the microbiological success and weights from random effects analysis in the mMITT-Set and PP-Set of patients treated with nitroxoline as compared to controls in the four studies analysed.** mMITT-modified microbiological intention to treat; PP-per protocol.

The eradication rates of *E. coli* in mono and mixed infection and Non-*E. coli* mono and mixed infections in the PP set are shown in Table [9](#Tab9){ref-type="table"}. As expected about 80% (79.0% vs 79.6%) of the patients in both groups had an *E. coli* infection either as mono or mixed infection with overall eradication rates of 94.3% and 96.3%, respectively. In the about 20% Non-*E. coli* infections the overall eradication was 83.3% and 93.0% in the nitroxoline and the control groups, respectively.Table 9**Microbiological success (eradication of bacteriuria) according to bacterial groups in the PP set**NitroxolineControlsMonoinfection *E. coli*129/138 (93.5%)141/145 (97.2%)Mixed infection *E. coli*20/20 (100%)17/19 (89.5%)Monoinfection with Non-*E. coli*28/34 (82.4%)37/40 (92.5%)Mixed infection with Non-*E. coli*7/8 (87.5%)2/2 (100%)Total184/200 (92.0%)197/206 (95.6%)

### Clinical efficacy {#Sec21}

In Figure [3](#Fig3){ref-type="fig"} the clinical efficacy in the PP sets are presented as reduction of symptoms as scored pre- and posttreatment. At the end of therapy no significant differences were seen in dysuria (pain during micturition), nocturia and flank/back pain between the two groups. Marked reductions of frequency (pollakisuria) and urgency (imperative micturition) were also seen (included) in both groups, which were, however, more pronounced in the controls. Considering the overall low scores achieved at the end of therapy, the differences may not be clinical relevant.Figure 3**Clinical efficacy (symptom scoring) in the PP treated by nitroxoline (n=193) and the controls (n= 203) (no assessment in 10 patients).**

### Global clinical assessment {#Sec22}

In the global clinical assessment (Table [10](#Tab10){ref-type="table"}) the patient (investigator) rated the treatment with nitroxoline in 91.2% (90.5%) and that with the control antibiotics in 96.2% (95.5%) as very good or good.Table 10**Global clinical assessment by the investigator in the PP set (no assessment in 103 patients)**AssessmentInvestigatorPatientGroupNitroxoline (n = 148)Controls (n = 158)Nitroxoline (n = 148)Controls (n = 158)Very good115 (77.7%)138 (87.3%)109 (73.6%)123 (77.8%)Good19 (12.8%)13 (8.2%)26 (17.6%)29 (18.4%)Satisfactory4 (2.7%)5 (3.2%)5 (3.4%)4 (2.5%)Moderate1 (0.7%)0 (0%)3 (2.0%)1 (0.6%)Insufficient9 (6.1%)2 (1.3%)5 (3.4%)1 (0.6%)p-value\*0.0060.143\*comparison of nitroxoline vs. controls (ordered probit regression with random center effect).

### Safety {#Sec23}

The treatments with nitroxoline and the control antibiotics were generally well tolerated (Table [11](#Tab11){ref-type="table"}). A total of 9.8% treated with nitroxoline and 7.8% treated with a control antibiotic reported any adverse event (p = 0.360). Only 5 (nitroxoline 3; controls 2) patients discontinued the treatment prematurely because of adverse events. The main adverse events were gastrointestinal disorders (nitroxoline 19; controls 9). In 3 patients of each group allergic reactions including itching, urticaria and in one case with papules/pustules (nitroxoline) were seen.Table 11**Adverse events**Adverse events (AE)NitroxolineControlsPatients (total)234 (100%)232 (100%)Patients with AEs^\#^23 (9.8%)18 (7.8%)Adverse events (total)3326Nervous system disordersHeadache34Dizziness-3Eye disordersEyelid swelling1-Cardiac and circulation disordersCirculation disorder-1Gastrointestinal disordersDysgeusia-1Nausea93Regurgitation11Gastralgia43Obstipation-1Diarrhoea5-Metabolim and nutrition disorderAnorexia1-Urinary disordersIncontinence1-Reproductive system disordersColpitis11Fluor vaginalis1-Tubal tumor-1Immune system disordersAllergy1\*1Skin and subcutaneous tissue disordersItching11Urticaria11Herpes labialis-1General disordersIntolerance1-Weakness1-Fever1-Musculoskeletal, connective tissue and bone disordersBack pain-1Flank pain-2Leg pain-1^\#^comparison of nitroxoline vs. controls (logistic regression with random center effect) p = 0.360; \*with papules/pustules.

In the laboratory parameters (Table [12](#Tab12){ref-type="table"}) no significant differences between critical values were observed between the two treatment groups (nitroxoline/controls), except a higher pretreatment (12.8% vs. 6.4%), but not posttreatment rate of critical values regarding the number of blood erythrocytes in the nitroxoline group.Table 12**Laboratory parameters before and after treatment in the safety-set**Critical valuesPretreatmentPosttreatmentNitroxolineContolsp-value\*NitroxolineContolsp-value\*Glucose (mg/dl)\< 55, \>16020/227 (8.8%)12/226 (5.3%)0.13812/206 (5.8%)7/207 (3.4%)0.242Creatinine (mg/dl)\> 1.81/228 (0.4%)1/227 (0.4%)0.9981/205 (0.5%)0/207 (0%)-Bilirubin (mg/dl)\< 0.1, \>2.03/226 (1.3%)1/227 (0.4%)0.3372/205 (1.0%)4/207 (1.9%)0.426SGOT --AST (U/l)\< 35, \> = 150224/226 (99.1%)225/226 (99.6%)0.570203/205 (99.0%)206/207 (99.5%)0.564SGPT - ALT (U/l)\< 35, \> = 150222/226 (98.2%)225/226 (99.6%)0.212204/205 (99.5%)207/207 (100%)-gamma-GT (U/l)\< 3, \>389/227 (4.0%)10/226 (4.4%)0.8079/205 (4.4%)6/207 (2.9%)0.412Sodium (mmol/l)\< 130, \>1508/228 (3.5%)6/226 (2.7%)0.60311/205 (5.4%)5/207 (2.4%)0.132Potassium (mmol/l)\< 3.6, \>6.022/228 (9.6%)19/226 (8.4%)0.62819/205 (9.3%)12/206 (5.8%)0.229Calcium (mmol/l)\< 8, \>11.5229/229 (100%)227/227 (100%)-206/206 (100%)206/206 (100%)-Hemoglobin (g/dl)\< 10, \>170/227 (0%)0/219 (0%)-1/201 (0.5%)2/204 (1.0%)0.582Hematocrit (%)\< 32, \>4725/227 (11.0%)33/220 (15.0%)0.19720/201 (10.0%)33/204 (16.2%)0.065Erythrocytes (Mio/μl)\< 4, \>5.129/227 (12.8%)14/220 (6.4%)0.02422/201 (10.9%)26/205 (12.7%)0.588Leucocytes (Tsd/μl)\< 4, \>11.325/227 (11.0%)21/220 (9.5%)0.60513/200 (6.5%)16/204 (7.8%)0.614Neutrophiles (%)\< 39, \>7522/225 (9.8%)37/221 (16.7%)0.03115/199 (7.5%)13/203 (6.4%)0.656Eosinophiles (%)\< 1, \>1010/223 (4.5%)19/219 (8.7%)0.08011/199 (5.5%)8/203 (3.9%)0.399Basophiles (%)0, \>1538/222 (17.1%)47/220 (21.4%)0.25729/199 (14.6%)38/203 (18.7%)0.266Lymphocytes (%)\< 10, \>509/221 (4.1%)12/220 (5.5%)0.3917/198 (3.5%)11/203 (5.4%)0.382Monocytes (%)\< 3, \>257/223 (3.1%)14/220 (6.4%)0.1179/199 (4.5%)6/203 (3.0%)0.410Retikulocytes (%)\< 0.5, \>2220/224 (98.2%)212/218 (97.2%)0.493198/200 (99.0%)200/205 (97.6%)0.227Thrombocytes (Tsd/μl)\< 150, \>45011/225 (4.9%)8/218 (3.7%)0.52910/201 (5.0%)8/204 (3.9%)0.608BSR (mm/1 h)\< 5, \>11134/203 (66.0%)124/202 (61.4%)0.343106/179 (59.2%)114/187 (61.0%)0.756BSR (mm/2 h)\> 2582/202 (40.6%)88/200 (44.0%)0.47044/178 (24.7%)57/186 (30.6%)0.207BSR-blood sedimentation rate.\*comparison of nitroxoline vs. controls, logistic regression with random center effect.

Discussion {#Sec24}
==========

When nitroxoline was first marketed in the European Union in 1962 for treatment and prophylaxis of UTI, microbiological and observational studies were considered sufficient. For this reason between 1962 and 1987 only uncontrolled studies were published not only for treatment and prophylaxis of uncomplicated, but also for treatment of complicated UTI including pyelonephritis, prostatitis and fungal infections in adults of both genders, and also in children. Only two prospective randomized studies, one for treatment of uncomplicated UTI in adults and one for prophylaxis of UTI in children, were published, both with low number of patients \[[@CR67]\],\[[@CR68]\]. Although these studies may not be considered highly evidential, they can at least contribute to establish the safety of nitroxoline in adults as well as in children together with the large postmarketing observational study.

When the requirements became more stringent for the renewal of the regulatory approval, finally achieved in Germany in 2005, four prospective randomized single blind studies were performed during 1992 and 1993 with cotrimoxazole and norfloxacin as controls. All four studies followed in essence the same protocol with the only difference that the treatment duration in women with sporadic uncomplicated UTI was five days and in women with acute episode of recurrent UTI was ten days. All four studies were of high quality achieving four out of maximum five Jadad scores \[[@CR73]\],\[[@CR74]\]. The bacterial spectra were similar between the studies with *E. coli* as most frequent pathogen ranging from 65% to 73%. There was no evidence that females suffering from recurrent UTI showed more resistant strains than those with sporadic UTI. During the years 1992--1993, when the studies were performed, the resistance rates for cotrimoxazole and norfloxacin were still very low. Both antibiotics were considered first line drugs for the treatment of uncomplicated UTI at that time \[[@CR10]\]. For all these reasons, including the data of all four studies in one meta-analysis was justified.

Since the clinical report forms (CRF) of the individual patients were available, an IPD meta-analysis could be performed, a specific type of systematic review \[[@CR75]\]. Rather than extracting summary (aggregate) data from study publications, the original research data are sought directly for each study. These data can then be re-analysed centrally and combined, if appropriate, in meta-analyses. IPD meta-analyses can improve the quality of data and their analysis and thus produce more reliable results \[[@CR76]\]. For this reason they are considered a 'gold standard' of systematic review in contrast to meta-analyses of aggregate data, which relates to information averaged or estimated across all individuals in a study. In a two step approach the individual participant data are first analysed in each separate study independently and then synthesized using a suitable model for meta-analysis of aggregate data. With individual participant data an analytic standardisation across the studies and a direct derivation of the information requested is possible, independent of significance or how it was reported.

Since at that time the microbiological evaluation was the primary aim practically in all UTI studies, a single-blind design was considered sufficient, because the eradication (primary aim) could be determined in an objective manner. Nevertheless, from todays point of view the single-blind design could be considered as a weakness of the studies, which may have affected mainly the clinical outcome and some subjective adverse events. However, the non-inferiority of nitroxoline for the eradication of bacteriuria as compared to the controls, cotrimoxazole and norfloxacin, is fairly well established by this IPD meta-analysis, whereas the individual studies contributed each between about 20 and 30% to the final results. Another shortcoming of the study may be, that after the test of cure the patients were not followed for a longer time. Therefore no information is available concerning the relapse rate after the test of cure visit.

Since the final microbiological evaluation in UTI studies is usually not performed at the end of treatment, but rather after the antibiotic substances are completely eliminated from the urinary tract and uropathogens, still present, have had time to multiply to significant numbers, the usual ITT and PP analyses may benefit good results, when patients drop out with favourable results after the end of treatment visit. These patients are considered a microbiological cure in the ITT set (last observation brought forward) and are drop outs for the classical PP analysis. Thus, possible treatment failures will be not recorded, because usually the reasons for dropping out after the treatment visit remains unknown. Therefore, a modified PP set was evaluated, in which all patients dropping out before test of cure were considered treatment failure (worst case scenario). Only if the same results can be achieved in all three evaluation sets, the overall result (non-inferiority) can be taken as proven, which was established by this IPD meta-analysis for nitroxoline as compared to the controls.

The current guidelines do usually not recommend a longer treatment duration of an acute episode in women with recurrent UTI than in those with sporadic UTI any more. For cotrimoxazole and fluoroquinolones even a 3-day therapy is considered sufficient in acute uncomplicated cystitis, but for the usage of macrocrystal nitrofurantoin also a 5-day therapy is recommended in the current guidelines \[[@CR11]\]--\[[@CR13]\]. Therefore a 5-day therapy of nitroxoline 250 mg tid should also be recommended as one of the first line options for the treatment of acute uncomplicated UTI (cystitis). Since about half of the female patients were pre- and postmenopausal in the studies meta-analysed, the dosage regimen and duration for both female groups can be considered the same, because in current guidelines an acute cystitis in otherwise healthy postmenopausal women is also considered as uncomplicated \[[@CR12]\].

Conclusions {#Sec25}
===========

Nitroxoline used for more than 50 years for the treatment and prophylaxis of adult patients and children suffering from UTI has shown good clinical efficacy and safety as published in 26 uncontrolled, in two earlier controlled and in one large postmarketing observational study including a total of more than 11,000 patients. This first IPD meta-analysis of four so far unpublished, prospective, randomized, comparative clinical studies with a total of 466 female patients with sporadic or recurrent uncomplicated UTI has demonstrated non-inferiority (10% non-inferiority margin) between treatment with nitroxoline versus controls (cotrimoxazole, norfloxacin). With a 5-day (sporadic UTI) and 10-day (recurrent UTI) treatment with nitroxoline 250 mg t.i.d. eradication of bacteriuria could be achieved in over 90% of the patients. The safety of nitroxoline was comparable with that of the controls. Adverse events, mainly gastrointestinal disorders and only a few allergic reactions, were reported only in 9.4% patients treated with nitroxoline and 7.8% with the control drugs. Combining the vast clinical experience obtained from studies published earlier and non-inferiority of bacteriological efficacy with nitroxoline versus the controls as documented by this high quality IPD meta-analysis and considering the world wide increase of resistance of uropathogens against cotrimoxazole and fluoroquinolones, which has not been seen with nitroxoline despite clinical usage for more than 20 years, nitroxoline should be reconsidered as one of the first line antibiotics for the treatment of uncomplicated UTI.
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